Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day
December 15, 2022 16:00 ET
|
Akoya Biosciences, Inc.
New products and partnerships further accelerate and simplify identification of actionable spatial signatures, creating unprecedented opportunities to improve patient outcomes Ready-to-use panels,...
Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
November 07, 2022 16:05 ET
|
Akoya Biosciences, Inc.
Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers Simplifies biomarker assay development and...
Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance
November 07, 2022 16:05 ET
|
Akoya Biosciences, Inc.
Q3 2022 revenue $18.9 million, 40% y/y growthRaising FY 2022 revenue guidance range to $73-75 million MARLBOROUGH, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA)...
Akoya to Participate at Three Upcoming Investor Conferences
November 03, 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming...
Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
October 11, 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya to Participate at Four Upcoming Investor Conferences
August 31, 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming...
Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
August 08, 2022 16:05 ET
|
Akoya Biosciences, Inc.
Q2 2022 revenue $17.9 million, 37% y/y growthRaising FY 2022 revenue guidance range to $71-74 million MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA)...
Akoya to Participate at Two Upcoming Investor Conferences
July 27, 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming...
Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022
July 12, 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
June 28, 2022 08:05 ET
|
Akoya Biosciences, Inc.
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...